In vitro experiments with three DLBCL cell lines representative of different genetic backgrounds showed that cells with high BCL-2 levels were resistant, whereas cells with high BECLIN-1-dependent autophagy were sensitive to doxorubicin. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.